Bispecific Antibody Production Bispecific Antibody Production

Bispecific Antibody Production

Antibody Production
  • Customized Service
  • Large Capacity
  • Strong Expertise

Overview

In the current competitive biotherapeutic market predominantly driven by antibody molecules, bispecific antibodies represent a key component of the next generation of antibody therapy. Immunoglobulin G (IgG), the most common type of antibody found in blood circulation, is monospecific and recognizes only a single antigen, with the exception of IgG4. In contrast, bispecific antibodies are designed to recognize and bind to two different targets at the same time.


This is useful as a therapeutic as they can be designed to redirect, for instance, immune cells such as T cells, to selectively engage and eliminate target tumor cells, by allowing effective binding of tumor cell receptors while also recruiting cytotoxic immune cells. In addition, bispecific antibodies can assist in the delivery of therapeutic payloads, such as toxins or drugs, to specific sites in the body.


Biointron has expressed over ten thousand of bispecific antibodies, and we have extensive experience in bispecific antibody production. We take pride in our ability to cater to any client request, offering a wide array of formats in bispecific antibody production.

Bispecific Antibody Production Overview
multispecific antibody productions 1
multispecific antibody productions 2
multispecific antibody productions 3
multispecific antibody productions 4
multispecific antibody productions 5
multispecific antibody productions 6
multispecific antibody productions 7
multispecific antibody productions 8
multispecific antibody productions 9
multispecific antibody productions 10
multispecific antibody productions 11
multispecific antibody productions 12
multispecific antibody productions 13
multispecific antibody productions 14
multispecific antibody productions 15
multispecific antibody productions 16
multispecific antibody productions 17
multispecific antibody productions 18
multispecific antibody productions 19
multispecific antibody productions 20
multispecific antibody productions 21
multispecific antibody productions 22
multispecific antibody productions 23
multispecific antibody productions 24

Some examples showcasing the various formats of Biointron's previous multispecific antibody productions.

Highlights

Customized Service

  • Any format can be expressed
  • Personalized approach for your research projects

Large Capacity

  • Automated Working stations
  • Multiple methods for purification and QC

Strong Expertise

  • 2-3 weeks (from sequences to BsAbs)
  • over ten thousand of bispecific antibodies have been delivered

Working Flowchart

Gene Synthesis

Plasmid construction and preparation

Transient expression

Affinity purification

Stringent quality control

Fast delivery

Bispecific Antibody Production
Service Details

Milestone Service Description Timeline Deliverables
Gene synthesis and cloning
  • Codon optimization and gene synthesis
  • Subcloning into an expression vector
  • Plasmid amplification and preparation
1 week
  • CoA report
  • Expression plasmid contain GOI
  • Purified antibody (SDS-PAGE >95%, endotoxin level < 1EU/mg, including SEC-HPLC detection)
Transient expression & purification
  • Co-Transfection of mammalian cells
  • Transient expression and purification
  • QC analysis
1-2 weeks

Case Study

  • Case 1:

    Format: Bispecific Antibody Production Case 1 Format

    Purity:SDS-Page>95%, SEC-HPLC>90%

    Bispecific Antibody Production Case 1
  • Case 2:

    Format: Bispecific Antibody Production Case 2 Format

    Purity: SDS-Page>95%, SEC-HPLC (two steps of purification)>98%

    Bispecific Antibody Production Case 2
“We like to ensure our clients are more than satisfied with our bispecific antibodies, offering a wide range of customizable formats to suit your precise research needs. Bispecific antibodies are transforming the landscape of medicine.”
Jiasha Huang
Jiasha Huang
Antibody Production Team

FAQs

  • How are bispecific antibodies produced?

    There are several approaches to producing bispecific antibodies, with the common methods being:

    • Knobs-into-holes: Replace a smaller amino acid with a larger amino acid in the CH3 region of an antibody chain to form “knobs”. Meanwhile, replace a larger amino acid in the other chain with a smaller amino acid to form “holes”.
    • Dual-Variable-Domain-IgG: A symmetrical molecular platform with four antigen binding sites and one pair of Fab domains. Each antibody arm utilizes short peptides to connect two variable regions.
    • Bispecific T-cell engager: Link the CD3 antibody scFv and the tumor-associated antigen to redirect T cells to cancer cells for more targeted killing.

    Many more platforms exist, with more information in this review by Ma et al.1

  • Why is choosing an appropriate format important?

    The format of a bispecific antibody will depend on the research purpose and aim, with the two main categories being the single-chain-based format and the IgG-based format. The IgG-based format can be further categorized into asymmetric and homodimerized formats. Presence of Fc regions, symmetry, specificity, and number of binding sites can be very different between bispecific antibodies.

    Due to their small size, single-chain-based formats are typically used to link immune cells to tumor cells, creating an immunological synapse. IgG-based formats have an extended blood half-life with their own crystalline fragment (Fc)-mediated functions.2

  • Why are bispecific antibodies useful as therapeutics?

    Bispecific antibodies offer a significant advantage compared to monospecific antibodies due to their unique ability to simultaneously target two different antigens or two epitopes of a single antigen. As biotherapeutics, bispecific antibodies have found applications in a wide range of fields, including cancer, hemophilia A, bone disorders, central nervous system infections and diseases.

  • What are some common applications for bispecific antibodies?

    The dual specificity of bispecific antibodies allows them to be used in a variety of applications, particularly in cancer:

    • To redirect immune effector cells to the proximity of tumor cells
    • To block signaling pathways
    • To target tumor angiogenesis
    • To block cytokines
    • As delivery vehicles3

References

  • Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021). Bispecific Antibodies: From Research to Clinical Application. Frontiers in Immunology, 12, 626616. https://doi.org/10.3389/fimmu.2021.626616
  • Yang, F., Wen, W., & Qin, W. (2017). Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. International Journal of Molecular Sciences, 18(1), 48. https://doi.org/10.3390/ijms18010048
  • Fan, G., Wang, Z., Hao, M. et al. Bispecific antibodies and their applications. J Hematol Oncol 8, 130 (2015). https://doi.org/10.1186/s13045-015-0227-0

Services & Products

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.